Roche wins Japan approval for personalized cancer drug Rozlytrek

60

Swiss drugmaker Roche’s push into personalized cancer medicines hit a milestone on Tuesday with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.

http://feeds.reuters.com/~r/reuters/healthNews/~3/AGpkXvjgcWk/roche-wins-japan-approval-for-personalized-cancer-drug-rozlytrek-idUSKCN1TJ0H4

- Advertisement -